EIKNEikon TherapeuticsSigning up patients
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Advanced Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 740 (planned)
- Started
- May 22, 2025
- Main results expected
- Dec 2035
- Fully finished
- Dec 2040
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: up to 5 years
Overall survival (OS)
Measured over: up to 5 years
Objective Response (OR) (Dose Optimization Only)
Measured over: up to 5 years
Adverse Events (AEs) (Dose Optimization Only)
Measured over: up to 2.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06697301 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC